Pharma marketing has been dominated by loud headlines this year. But FDA has only listed a proposed rule on the 2026 Unified Agenda that would revise 21 CFR 202.1 and eliminate that option for broadcast DTC ads, with a notice expected in late 2026. The loudest signals so far have been publicity, not policy. The rule itself hasn’t been written, and agencies routinely exceed their planned timeframes, sometimes by years.
That gap doesn’t mean marketers can wait. The proposal follows a September 2025 crackdown that included roughly 100 cease-and-desist letters and expanded social media oversight, and recent untitled letters against major brands show exactly where scrutiny is landing today. Understanding what’s driving this enforcement now is the clearest window into what a post-adequate-provision world could look like, and which campaigns are most exposed. In the full article, we break down the enforcement trends shaping 2026, what’s actually in the proposed rule, and the concrete steps Clinical and Regulatory teams should take today to prepare.
Read the entire article.
Read the full article
"*" indicates required fields
